ORNBV Stock Overview
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Orion Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €33.12 |
| 52 Week High | €46.97 |
| 52 Week Low | €31.86 |
| Beta | 0.35 |
| 1 Month Change | -3.07% |
| 3 Month Change | -24.35% |
| 1 Year Change | -28.93% |
| 3 Year Change | -8.86% |
| 5 Year Change | 11.78% |
| Change since IPO | 138.27% |
Recent News & Updates
Recent updates
Earnings Beat: Orion Oyj Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 16
Why Investors Shouldn't Be Surprised By Orion Oyj's (HEL:ORNBV) P/E
Feb 01Orion Oyj (HEL:ORNBV) Has A Pretty Healthy Balance Sheet
Jan 11Are Investors Undervaluing Orion Oyj (HEL:ORNBV) By 43%?
Nov 28We Think That There Are More Issues For Orion Oyj (HEL:ORNBV) Than Just Sluggish Earnings
Nov 03Orion Oyj (HEL:ORNBV) Could Easily Take On More Debt
Oct 05Orion Oyj's (HEL:ORNBV) Intrinsic Value Is Potentially 51% Above Its Share Price
Aug 18Is Orion Oyj (HEL:ORNBV) Using Too Much Debt?
Jun 21A Look At The Intrinsic Value Of Orion Oyj (HEL:ORNBV)
May 16Here's Why We Think Orion Oyj (HEL:ORNBV) Is Well Worth Watching
Apr 07Orion Oyj (HEL:ORNBV) Could Easily Take On More Debt
Mar 20Orion Oyj's (HEL:ORNBV) Upcoming Dividend Will Be Larger Than Last Year's
Feb 12A Look At The Intrinsic Value Of Orion Oyj (HEL:ORNBV)
Feb 07Is Orion Oyj (HEL:ORNBV) Trading At A 29% Discount?
Oct 13Orion Oyj (HEL:ORNBV) Seems To Use Debt Quite Sensibly
Sep 22This Just In: Analysts Are Boosting Their Orion Oyj (HEL:ORNBV) Outlook for This Year
Jul 21Is There An Opportunity With Orion Oyj's (HEL:ORNBV) 34% Undervaluation?
Jul 10Does Orion Oyj (HEL:ORNBV) Have A Healthy Balance Sheet?
Jun 14Are Investors Undervaluing Orion Oyj (HEL:ORNBV) By 34%?
Apr 11Is Orion Oyj (HEL:ORNBV) A Risky Investment?
Mar 09Orion Oyj's (HEL:ORNBV) Intrinsic Value Is Potentially 37% Above Its Share Price
Jan 09Is Orion Oyj (HEL:ORNBV) Trading At A 31% Discount?
Oct 05Is Orion Oyj (HEL:ORNBV) Using Too Much Debt?
Aug 19Are Investors Undervaluing Orion Oyj (HEL:ORNBV) By 20%?
Jul 07Shareholder Returns
| ORNBV | FI Pharmaceuticals | FI Market | |
|---|---|---|---|
| 7D | 2.4% | 3.2% | 1.4% |
| 1Y | -28.9% | 5.7% | -12.9% |
Return vs Industry: ORNBV underperformed the Finnish Pharmaceuticals industry which returned 5.7% over the past year.
Return vs Market: ORNBV underperformed the Finnish Market which returned -12.9% over the past year.
Price Volatility
| ORNBV volatility | |
|---|---|
| ORNBV Average Weekly Movement | 2.6% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FI Market | 7.3% |
| 10% least volatile stocks in FI Market | 3.1% |
Stable Share Price: ORNBV's share price has been volatile over the past 3 months.
Volatility Over Time: ORNBV's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | 3,632 | Liisa Hurme | www.orion.fi |
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease.
Orion Oyj Fundamentals Summary
| ORNBV fundamental statistics | |
|---|---|
| Market cap | €4.67b |
| Earnings (TTM) | €216.80m |
| Revenue (TTM) | €1.19b |
21.5x
P/E Ratio3.9x
P/S RatioIs ORNBV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORNBV income statement (TTM) | |
|---|---|
| Revenue | €1.19b |
| Cost of Revenue | €531.90m |
| Gross Profit | €657.80m |
| Other Expenses | €441.00m |
| Earnings | €216.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
| Earnings per share (EPS) | 1.54 |
| Gross Margin | 55.29% |
| Net Profit Margin | 18.22% |
| Debt/Equity Ratio | 21.6% |
How did ORNBV perform over the long term?
See historical performance and comparisonDividends
4.9%
Current Dividend Yield105%
Payout RatioDoes ORNBV pay a reliable dividends?
See ORNBV dividend history and benchmarks| Orion Oyj dividend dates | |
|---|---|
| Ex Dividend Date | Oct 15 2024 |
| Dividend Pay Date | Oct 23 2024 |
| Days until Ex dividend | 173 days |
| Days until Dividend pay date | 181 days |
Does ORNBV pay a reliable dividends?
See ORNBV dividend history and benchmarks